Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Product approval in US

7 Feb 2008 07:00

ViaLogy PLC07 February 2008 VIALOGY SPM product successfully tested and approved by US National Incident Management System London, 7 February, 2008: ViaLogy PLC (LSE: VIY), a leading innovator ofreal-time network-centric signal processing platforms, announces that itsproduct SPMTM (Sensor Policy ManagerTM), for sensor interoperability andintegration, has received unqualified approval from America's National IncidentManagement System Support Center (NIMS SC), a division of The Department ofHomeland Security's (DHS) Federal Emergency Management Agency (FEMA). NIMSawarded SPM top marks in all tested categories. NIMS has been established by the US government to deal with national emergencysituations, including terrorist attacks. It enables responders from differentjurisdictions and disciplines to work together to respond to natural disastersand emergencies, including acts of terrorism. Benefits include a unifiedapproach to incident management; standard command and management structures; andemphasis on preparedness, mutual aid and resource management. Key to any emergency situation response is the ability of all the differentsensors involved to integrate information and prioritise alerts. ViaLogy's SPMis designed specifically to enable this to happen seamlessly and immediately. Inrecent weeks NIMS engineers have been subjecting the product to extensive andrigorous testing. They have determined that SPM meets all its requiredstandards. "The product is consistent with the concepts and principles of NIMS,"concludes the Evaluation Report. "It is applicable to all 15 Emergency SupportFunctions, all six hazard groups, and to a multi-jurisdictional response." Ineach case the tests marked SPM five out of five. In addition, the report praisedthe speed at which SPM could be incorporated in any sensor and the fact that ittakes just 20 hours to fully train an SPM operator. "We are absolutely delighted with the NIMS validation," said Robert W. Dean,President and CEO of ViaLogy. "Our SPM product is designed to enable aco-ordinated proactive response by all the emergency services involved indealing with an emergency incident. Quite simply, it will help to save lives. "Most importantly, the system is sensor agnostic so it can create instantcommunication between a wide variety of sensors used in a range of safety,security and emergency response applications." ViaLogy is also participating in additional validation demonstrations with anumber of manufacturers involved in producing and integrating commercialsecurity systems. ends ViaLogyRobert W Dean, President/CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)Terry Bond, Chairman - UK & Europe +44 (0)1235 834734 Nominated Advisor (Seymour Pierce)Mark Percy +44 (0)20 7107 8000 PR Consultants - Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications and sensor fusion. ViaLogy is currentlydeploying and designing computational systems, powered by its patentedtechnologies, for applications in life sciences, public safety and security,surveillance, defense and geoseismology. Vialogy focuses on market drivenproblems where automation, timeliness, quality and reliability of informationprocessing are essential. ViaLogy's core competency incorporates rapidly andaccurately detecting weak signals buried in high noise background and clutter.This technology can be employed to solve problems involving sensor integrationand information overload challenges involving video, telephony and controlsensors, as well as for enhancement of numerous signal processing applications.For more information, visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:36 pmRNSPrice Monitoring Extension
27th Mar 20203:00 pmRNSIssue of Share Options
25th Mar 20207:00 amRNSContract manufacturing agreement for COVID-19 test
16th Mar 20204:41 pmRNSSecond Price Monitoring Extn
16th Mar 20204:36 pmRNSPrice Monitoring Extension
13th Mar 202011:51 amRNSHolding(s) in Company
10th Mar 20207:00 amRNSAcquisition of French distribution channel
17th Feb 20207:00 amRNSCE Marking Technical File submission
14th Feb 202011:00 amRNSMedilink Award win for Outstanding Achievement
14th Feb 20207:00 amRNSTGA approves DPYD for sale in Australia
5th Dec 201912:10 pmRNSThe Healthcare+ Expo Taiwan
2nd Dec 20197:00 amRNSHalf-year Report
29th Nov 201912:05 pmRNSBionow Double Award Win
28th Nov 20197:00 amRNSOpening of New Facilities and Corporate HQ
15th Nov 20197:00 amRNSPrivate Investor Presentation
12th Nov 201910:12 amRNSNotice of Results
6th Nov 20191:52 pmRNSCapital Markets Day
1st Nov 20197:00 amRNSDirector/PDMR Shareholding
31st Oct 20197:00 amRNSLaunch of Yourgene FlexT Analysis Software
30th Oct 20197:00 amRNSIssue of Share Options
15th Oct 20197:00 amRNSAmerican Society of Human Genetics Annual Meeting
14th Oct 20197:00 amRNSHalf year trading update
1st Oct 20197:00 amRNSPrivate Investor Presentation
26th Sep 20197:00 amRNSCE-IVD Certification renewal
18th Sep 20197:00 amRNSLaunch of DPYD chemotoxicity diagnostic assay
17th Sep 20195:50 pmRNSResult of AGM
17th Sep 20197:00 amRNSAGM Statement
20th Aug 20197:00 amRNSNotice of AGM
19th Aug 201910:35 amRNSChange of Registered Office
16th Aug 20193:49 pmRNSHolding(s) in Company
16th Aug 20199:06 amRNSDirectorate Change
12th Aug 20197:00 amRNSAmendment to Share Options
1st Aug 20197:00 amRNSDirector/PDMR Shareholding
29th Jul 20197:00 amRNSAppointment of Director
10th Jul 20197:00 amRNSFinal Results, Business Update and Director Change
27th Jun 20197:00 amRNSNotice of Results
24th Jun 20197:00 amRNSYourgene participates in key global conferences
3rd Jun 20197:01 amRNSDirector's dealing
3rd Jun 20197:00 amRNSIssue of Share Options
9th May 20194:07 pmRNSDirector's dealing
9th May 20197:00 amRNSDirectors' dealing & warrant extension
1st May 20198:05 amRNSTotal Voting Rights
26th Apr 20195:12 pmRNSHolding(s) in Company
26th Apr 20195:01 pmRNSHolding(s) in Company
25th Apr 20194:40 pmRNSCompletion of Acquisition
18th Apr 20197:00 amRNSResults of Placing and Subscription
17th Apr 20194:50 pmRNSAppointment of Sole Corporate Broker
17th Apr 20194:48 pmRNSProposed Acquisition, Placing & Subscription
8th Apr 20197:00 amRNSFull-year Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.